P Nigel Leigh
Overview
Explore the profile of P Nigel Leigh including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
144
Citations
7861
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Vaughan D, Fumi R, Theilmann Jensen M, Hodgson M, Georgiades T, Wu L, et al.
Mov Disord
. 2024 Sep;
39(12):2285-2291.
PMID: 39301998
Background: Seed amplification assay (SAA) testing has been developed as a biomarker for the diagnosis of α-synuclein-related neurodegenerative disorders. Objective: The objective of this study was to assess the rate...
2.
Shojaie A, Al Khleifat A, Garrahy S, Habash-Bailey H, Thomson R, Opie-Martin S, et al.
Amyotroph Lateral Scler Frontotemporal Degener
. 2024 Sep;
25(7-8):702-707.
PMID: 39218010
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by the gradual death of motor neurons in the brain and spinal cord, leading to fatal paralysis. Socioeconomic status (SES) is...
3.
Alarcan H, Bruno C, Emond P, Raoul C, Vourch P, Corcia P, et al.
Ann N Y Acad Sci
. 2024 May;
1536(1):82-91.
PMID: 38771698
Amyotrophic lateral sclerosis (ALS) is a devastating motor neuron disease. The immunosuppressive functions of regulatory T lymphocytes (Tregs) are impaired in ALS, and correlate to disease progression. The phase 2a...
4.
Kobylecki C, Chelban V, Goh Y, Michou E, Fumi R, Theilmann Jensen M, et al.
Eur J Neurol
. 2024 Feb;
31(6):e16258.
PMID: 38407533
Background: Multiple system atrophy (MSA), progressive supranuclear palsy (PSP) and corticobasal syndrome (CBS) show a high prevalence and rapid progression of dysphagia, which is associated with reduced survival. Despite this,...
5.
Whiteside D, Street D, Murley A, Jones P, Malpetti M, Ghosh B, et al.
Hum Brain Mapp
. 2023 Jun;
44(11):4239-4255.
PMID: 37269181
There is a pressing need to understand the factors that predict prognosis in progressive supranuclear palsy (PSP) and corticobasal syndrome (CBS), with high heterogeneity over the poor average survival. We...
6.
Progression of atypical parkinsonian syndromes: PROSPECT-M-UK study implications for clinical trials
Street D, Jabbari E, Costantini A, Jones P, Holland N, Rittman T, et al.
Brain
. 2023 Mar;
146(8):3232-3242.
PMID: 36975168
The advent of clinical trials of disease-modifying agents for neurodegenerative disease highlights the need for evidence-based end point selection. Here we report the longitudinal PROSPECT-M-UK study of progressive supranuclear palsy...
7.
Simoes F, Joilin G, Peters O, Schneider L, Priller J, Spruth E, et al.
Int J Mol Sci
. 2022 Dec;
23(23).
PMID: 36498882
Objective markers for the neurodegenerative disorder progressive supranuclear palsy (PSP) are needed to provide a timely diagnosis with greater certainty. Non-coding RNA (ncRNA), including microRNA, piwi-interacting RNA, and transfer RNA,...
8.
Profiling non-coding RNA expression in cerebrospinal fluid of amyotrophic lateral sclerosis patients
Joilin G, Gray E, Thompson A, Talbot K, Leigh P, Newbury S, et al.
Ann Med
. 2022 Oct;
54(1):3069-3078.
PMID: 36314539
Introduction: Objective biomarkers for the fatal neurodegenerative disease amyotrophic lateral sclerosis or motor neuron disease (ALS/MND) are critical for diagnosis, drug development, clinical trials, and insight into disease pathology. Key...
9.
Chelban V, Nikram E, Perez-Soriano A, Wilke C, Foubert-Samier A, Vijiaratnam N, et al.
Brain
. 2022 Jul;
145(12):4398-4408.
PMID: 35903017
Disease-modifying treatments are currently being trialled in multiple system atrophy. Approaches based solely on clinical measures are challenged by heterogeneity of phenotype and pathogenic complexity. Neurofilament light chain protein has...
10.
Balendra R, Jones A, Al Khleifat A, Chiwera T, Wicks P, Young C, et al.
Amyotroph Lateral Scler Frontotemporal Degener
. 2022 Jul;
24(1-2):71-81.
PMID: 35852375
: Amyotrophic lateral sclerosis (ALS) shows considerable clinical heterogeneity, which affects clinical trials. A clinical staging system has been proposed for ALS with potential applications in patient care, research, trial...